Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees

This article was originally published in The Gray Sheet

Executive Summary

Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc

You may also be interested in...



CMS Bends Knee Injection Code Policy Under Pressure From Genzyme

CMS reversed course with a Dec. 14 decision to pay for viscosupplement injections for osteoarthritic knees under four distinct codes in 2007 following persistent pressure from the products' manufacturers

CMS Bends Knee Injection Code Policy Under Pressure From Genzyme

CMS reversed course with a Dec. 14 decision to pay for viscosupplement injections for osteoarthritic knees under four distinct codes in 2007 following persistent pressure from the products' manufacturers

Knee injection HCPCS code

CMS finalizes its proposal to assign all hyaluronic acid-based knee injection treatments for osteoarthritis to a single HCPCS code, effective Jan. 1. The current two-code system differentiates between chemically altered and natural hyaluronate products. Genzyme's Synvisc falls under the former category and is currently paid more than its competitors. Johnson & Johnson/DePuy Mitek (Orthovisc), Sanofi-Aventis (Hyalgan) and Smith & Nephew (Supartz) have petitioned CMS to create distinct codes for their respective devices based on molecular weight (1"The Gray Sheet" June 20, 2005, p. 3)...

Related Content

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel